1
|
Martins JC, Maier J, Gianoli C, Neppl S, Dedes G, Alhazmi A, Veloza S, Reiner M, Belka C, Kachelrieß M, Parodi K. Towards real-time EPID-based 3D in vivo dosimetry for IMRT with Deep Neural Networks: A feasibility study. Phys Med 2023; 114:103148. [PMID: 37801811 DOI: 10.1016/j.ejmp.2023.103148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 08/17/2023] [Accepted: 09/22/2023] [Indexed: 10/08/2023] Open
Abstract
We investigate the potential of the Deep Dose Estimate (DDE) neural network to predict 3D dose distributions inside patients with Monte Carlo (MC) accuracy, based on transmitted EPID signals and patient CTs. The network was trained using as input patient CTs and first-order dose approximations (FOD). Accurate dose distributions (ADD) simulated with MC were given as training targets. 83 pelvic CTs were used to simulate ADDs and respective EPID signals for subfields of prostate IMRT plans (gantry at 0∘). FODs were produced as backprojections from the EPID signals. 581 ADD-FOD sets were produced and divided into training and test sets. An additional dataset simulated with gantry at 90∘ (lateral set) was used for evaluating the performance of the DDE at different beam directions. The quality of the FODs and DDE-predicted dose distributions (DDEP) with respect to ADDs, from the test and lateral sets, was evaluated with gamma analysis (3%,2 mm). The passing rates between FODs and ADDs were as low as 46%, while for DDEPs the passing rates were above 97% for the test set. Meaningful improvements were also observed for the lateral set. The high passing rates for DDEPs indicate that the DDE is able to convert FODs into ADDs. Moreover, the trained DDE predicts the dose inside a patient CT within 0.6 s/subfield (GPU), in contrast to 14 h needed for MC (CPU-cluster). 3D in vivo dose distributions due to clinical patient irradiation can be obtained within seconds, with MC-like accuracy, potentially paving the way towards real-time EPID-based in vivo dosimetry.
Collapse
Affiliation(s)
- Juliana Cristina Martins
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, Garching b. München, 85748, Germany.
| | - Joscha Maier
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany.
| | - Chiara Gianoli
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, Garching b. München, 85748, Germany.
| | - Sebastian Neppl
- Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistraße 15, Munich, 81377, Germany.
| | - George Dedes
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, Garching b. München, 85748, Germany.
| | - Abdulaziz Alhazmi
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, Garching b. München, 85748, Germany.
| | - Stella Veloza
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, Garching b. München, 85748, Germany.
| | - Michael Reiner
- Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistraße 15, Munich, 81377, Germany.
| | - Claus Belka
- Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistraße 15, Munich, 81377, Germany.
| | - Marc Kachelrieß
- German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany; Heidelberg University, Grabengasse 1, Heidelberg, 69117, Germany.
| | - Katia Parodi
- Department of Medical Physics, Faculty of Physics, Ludwig-Maximilians-Universität München, Am Coulombwall 1, Garching b. München, 85748, Germany.
| |
Collapse
|
2
|
Stevens S, Moloney S, Blackmore A, Hart C, Rixham P, Bangiri A, Pooler A, Doolan P. IPEM topical report: guidance for the clinical implementation of online treatment monitoring solutions for IMRT/VMAT. Phys Med Biol 2023; 68:18TR02. [PMID: 37531959 DOI: 10.1088/1361-6560/acecd0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 08/02/2023] [Indexed: 08/04/2023]
Abstract
This report provides guidance for the implementation of online treatment monitoring (OTM) solutions in radiotherapy (RT), with a focus on modulated treatments. Support is provided covering the implementation process, from identification of an OTM solution to local implementation strategy. Guidance has been developed by a RT special interest group (RTSIG) working party (WP) on behalf of the Institute of Physics and Engineering in Medicine (IPEM). Recommendations within the report are derived from the experience of the WP members (in consultation with manufacturers, vendors and user groups), existing guidance or legislation and a UK survey conducted in 2020 (Stevenset al2021). OTM is an inclusive term representing any system capable of providing a direct or inferred measurement of the delivered dose to a RT patient. Information on each type of OTM is provided but, commensurate with UK demand, guidance is largely influenced byin vivodosimetry methods utilising the electronic portal imager device (EPID). Sections are included on the choice of OTM solutions, acceptance and commissioning methods with recommendations on routine quality control, analytical methods and tolerance setting, clinical introduction and staffing/resource requirements. The guidance aims to give a practical solution to sensitivity and specificity testing. Functionality is provided for the user to introduce known errors into treatment plans for local testing. Receiver operating characteristic analysis is discussed as a tool to performance assess OTM systems. OTM solutions can help verify the correct delivery of radiotherapy treatment. Furthermore, modern systems are increasingly capable of providing clinical decision-making information which can impact the course of a patient's treatment. However, technical limitations persist. It is not within the scope of this guidance to critique each available solution, but the user is encouraged to carefully consider workflow and engage with manufacturers in resolving compatibility issues.
Collapse
Affiliation(s)
| | - Stephen Moloney
- University Hospitals Dorset NHS Foundation Trust, Poole, United Kingdom
| | | | - Clare Hart
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Philip Rixham
- Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
| | - Anna Bangiri
- Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
| | - Alistair Pooler
- Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom
| | | |
Collapse
|
3
|
Chen L, Zhang Z, Yu L, Peng J, Feng B, Zhao J, Liu Y, Xia F, Zhang Z, Hu W, Wang J. A clinically relevant online patient QA solution with daily CT scans and EPID-based in vivo dosimetry: a feasibility study on rectal cancer. Phys Med Biol 2022; 67. [DOI: 10.1088/1361-6560/ac9950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 10/11/2022] [Indexed: 11/06/2022]
Abstract
Abstract
Objective. Adaptive radiation therapy (ART) could protect organs at risk (OARs) while maintain high dose coverage to targets. However, there is still a lack of efficient online patient quality assurance (QA) methods, which is an obstacle to large-scale adoption of ART. We aim to develop a clinically relevant online patient QA solution for ART using daily CT scans and EPID-based in vivo dosimetry. Approach. Ten patients with rectal cancer at our center were included. Patients’ daily CT scans and portal images were collected to generate reconstructed 3D dose distributions. Contours of targets and OARs were recontoured on these daily CT scans by a clinician or an auto-segmentation algorithm, then dose-volume indices were calculated, and the percent deviation of these indices to their original plans were determined. This deviation was regarded as the metric for clinically relevant patient QA. The tolerance level was obtained using a 95% confidence interval of the QA metric distribution. These deviations could be further divided into anatomically relevant or delivery relevant indicators for error source analysis. Finally, our QA solution was validated on an additional six clinical patients. Main results. In rectal cancer, the 95% confidence intervals of the QA metric for PTV ΔD
95 (%) were [−3.11%, 2.35%], and for PTV ΔD
2 (%) were [−0.78%, 3.23%]. In validation, 68% for PTV ΔD
95 (%), and 79% for PTV ΔD
2 (%) of the 28 fractions are within tolerances of the QA metrics. one patient’s dosimetric impact of anatomical variations during treatment were observed through the source of error analysis. Significance. The online patient QA solution using daily CT scans and EPID-based in vivo dosimetry is clinically feasible. Source of error analysis has the potential for distinguishing sources of error and guiding ART for future treatments.
Collapse
|